Evidence map›Paper›PMID 23372160›Full record

ArticleThe Journal of biological chemistry2013

Homotrimeric macrophage migration inhibitory factor (MIF) drives inflammatory responses in the corneal epithelium by promoting caveolin-rich platform assembly in response to infection.

Thomas Reidy, Alexander Rittenberg, Markryan Dwyer, Samantha D'Ortona, Gerald Pier, Mihaela Gadjeva

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Caveolins and caveolae in ocular physiology and pathophysiology.Progress in retinal and eye research · 2017
    Review
  5. Article
  6. Article
  7. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Thomas ReidyDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Alexander RittenbergDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Markryan DwyerDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Samantha D'OrtonaDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Gerald PierDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Mihaela GadjevaDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115. Electronic address: mgadjeva@rics.bwh.harvard.edu.
Brigham and Women's Hospital · USHarvard University · US

Funding

Pathogensis of Bacterial corneal infectionR01EY016144 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI PIER, GERALD B · 2005 to 2018
$5.6M
Novel treatment strategies to regulate inflammation during P.aeruginosa keratitisR01EY022054 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI GADJEVA, MIHAELA GUEORGUIEVA · 2012 to 2020
$4.0M
Inhibition of MIF is protective against Pseudomonas aeruginosa-eye infectionR21EY019944 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI GADJEVA, MIHAELA GUEORGUIEVA · 2010 to 2011
$477k
NEI NIH HHS 1R21EY019944NEI NIH HHS R01 EY016144NEI NIH HHS R01EY016144NEI NIH HHS R01 EY022054NEI NIH HHS R21 EY019944
6 · The paper itself

Abstract

Acute inflammation that arises during Pseudomonas aeruginosa-induced ocular infection can trigger tissue damage resulting in long term impairment of visual function, suggesting that the appropriate treatment strategy should include the use of anti-inflammatory agents in addition to antibiotics. We recently identified a potential target for modulation during ocular infection, macrophage migration inhibitory factor (MIF). MIF deficiency protected mice from inflammatory-mediated corneal damage resulting from acute bacterial keratitis. To gain a better understanding of the molecular mechanisms of MIF activity, we analyzed the oligomeric states and functional properties of MIF during infection. We found that in human primary corneal cells infected with P. aeruginosa, MIF is primarily in a homotrimeric state. Homotrimeric MIF levels correlated with the severity of infection in the corneas of infected mice, suggesting that the MIF homotrimers were the functionally active form of MIF. During infection, human primary corneal cells released more IL-8 when treated with recombinant, locked MIF trimers than when treated with lower MIF oligomers. MIF promoted P. aeruginosa-induced IL-8 responses via the formation of caveolin-1-rich "signaling hubs" in the corneal cells that led to elevated MAPK p42/p44 activation and sustained inflammatory signaling. These findings suggest that inhibiting homotrimerization of MIF or the functional activities of MIF homotrimers could have therapeutic benefits during ocular inflammation.

Indexed as

AnimalsCaveolinsCells, CulturedConjunctivitis, BacterialEpithelium, CornealHumansInflammation MediatorsInterleukin-8Macrophage Migration-Inhibitory FactorsMAP Kinase Signaling SystemMembrane MicrodomainsMiceMice, Inbred BALB CMice, Inbred C57BLPrimary Cell CultureProtein Structure, QuaternaryCaveolinsCXCL8 protein, humanInflammation MediatorsInterleukin-8Macrophage Migration-Inhibitory Factors

Identifiers

PMID23372160
PMCPMC3605645
OpenAlexW2024668214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.